Secretomix®
undisclosedplatform · high
Produce off-the-shelf, disease-modifying, cell-free stem cell-derived secretome therapeutic products for degenerative and underdevelopment conditions.
Platform technology that guides stem cells to produce multi-component secretome biologics containing paracrine factors such as miRNA, extracellular vesicles including exosomes, and proteins such as growth factors.
Micregen publicly describes Secretomix® as its platform technology and lists a pipeline page, but no specific named clinical-stage pipeline assets are supplied.